A clinical trial studying the effect of intake of alpha‐lipoic acid on serum resistin levels in T2DM patients with chronic periodontitis demonstrated that systemic administration of alpha‐lipoic acid as an adjunct therapy to scaling and root planning significantly decreased serum resistin and HbA1c in the patients.223. The gene discussed is RETN; the disease is periodontitis.